Nigeria to receive HIV prevention drug in March, says NACA
Nigeria to receive HIV prevention drug in March, says NACA—and for a country still battling new infections, uneven access to prevention services, and stigma, the announcement lands like a rare piece of good news in public health.
The National Agency for the Control of AIDS (NACA) says Nigeria is set to take delivery of lenacapavir, a long-acting injectable HIV prevention medicine, in March 2026. The agency said it is advancing preparations for introduction and rollout of the drug as pre-exposure prophylaxis (PrEP). 
In the same update, NACA’s public relations office said regulatory approval has been secured from the National Agency for Food and Drug Administration and Control (NAFDAC), positioning the country for a phased start once the consignments arrive. 
That is the core of the story: Nigeria to receive HIV prevention drug in March, says NACA, and the government is framing it as a step toward faster progress in HIV prevention.
What lenacapavir is, and why it’s different
Lenacapavir is a long-acting medicine used for HIV prevention as PrEP, delivered as an injection designed to provide protection for about six months per dose—meaning a person would typically need it twice a year. 
That dosing schedule is the headline innovation. Many people struggle with daily pills, and even shorter-interval options can be hard to maintain. A twice-yearly injection changes the conversation from daily discipline to clinic access and follow-up. It is one reason global health agencies have described lenacapavir as a potentially game-changing prevention tool. 
So when Nigeria to receive HIV prevention drug in March, says NACA, it is not just a new product entering the market. It is a new style of prevention that could fit real-life routines better—especially for people who find daily PrEP difficult.
The evidence behind the excitement
The scientific case for lenacapavir as PrEP is built on large late-stage studies (often referenced as PURPOSE trials) and subsequent regulatory and guideline actions internationally.
• The World Health Organization issued guidelines recommending twice-yearly injectable lenacapavir as an additional PrEP option in mid-2025. 
• Gilead, the manufacturer, announced U.S. FDA approval for lenacapavir for HIV prevention in June 2025, citing phase 3 data in which ≥99.9% of participants remained HIV negative. 
• The U.S. CDC’s MMWR also summarizes the evidence base and situates lenacapavir among long-acting PrEP options, pointing to the key clinical trials. 
This matters because Nigeria to receive HIV prevention drug in March, says NACA is not just a local promise; it is tied to a global shift in prevention tools and guidance.
https://ogelenews.ng/nigeria-to-receive-hiv-prevention-drug
What NACA is actually promising (and what it isn’t)
NACA’s message is about arrival and preparation: consignments expected in March, and groundwork underway for rollout. 
What it is not promising—at least not yet—is instant nationwide access for everyone who might want it. A phased rollout is normal for a new medicine, especially one that requires supply planning, training, cold-chain considerations where relevant, clinic protocols, and clear rules on eligibility and follow-up testing.
That nuance is important for your readers. Nigeria to receive HIV prevention drug in March, says NACA does not automatically mean “available everywhere in March.” It means the pipeline is opening, and the system is preparing.
The public health “why”: prevention has been stuck
WHO has warned that global progress on HIV prevention has not moved fast enough, and that expanding prevention options—especially long-acting choices—could help accelerate impact. 
For Nigeria, the stakes are practical: every prevention method has drop-off points. Condoms require negotiation and consistent use. Daily pills require routine. Clinic-based services require access. A twice-yearly injection reduces one barrier (daily adherence) but raises others (clinic readiness, appointment systems, reliable supply).
Still, the upside is clear: Nigeria to receive HIV prevention drug in March, says NACA is a chance to add a powerful option to the country’s combination prevention toolbox.
What to watch next
If you’re tracking this beyond the headline Nigeria to receive HIV prevention drug in March, says NACA, these are the next hard-news questions:
1. Rollout plan: Which states and facilities start first, and what does “phased” mean in timelines? 
2. Access rules: Who qualifies, what counselling/testing steps are required, and how often follow-up happens (global guidance stresses HIV testing approaches alongside long-acting PrEP). 
3. Financing and supply: Will it be donor-supported, government-funded, insured, or mixed—and will supply be steady enough to avoid interruptions? (This is where many prevention programmes struggle.) 
Until those details are published, the most accurate framing remains the official one: Nigeria to receive HIV prevention drug in March, says NACA—with the real story being whether Nigeria can turn arrival into equitable access.
And yes, because readers keep searching it: Nigeria to receive HIV prevention drug in March, says NACA is the line that will dominate the public conversation in the coming weeks.
https://punchng.com/nigeria-to-receive-hiv-prevention-drug-in-march-says-naca
